The novel sodium glucose transporter 2 inhibitor dapagliflozin sustains pancreatic function and preserves islet morphology in obese, diabetic rats

Diabetes, Obesity and Metabolism

Volumn 12, Issue 11, 2010, Pages 1004-1012

  Macdonald, F R ^a   Peel, J E ^a   Jones, H B ^a   Mayers, R M ^a   Westgate, L ^a   Whaley, J M ^b   Poucher, S M ^a  

^a ASTRAZENECA   (United Kingdom)

^b BRISTOL MYERS SQUIBB RESEARCH AND DEVELOPMENT   (United States)

Author keywords

Diabetes mellitus; SGLT2 inhibitor; Zucker diabetic fatty rat; cell

Indexed keywords

DAPAGLIFLOZIN; GLUCOSE; GLYCOSYLATED HEMOGLOBIN;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; CONTROLLED STUDY; FEMALE; GLUCOSE BLOOD LEVEL; GLUCOSE CLAMP TECHNIQUE; HEMOGLOBIN BLOOD LEVEL; HYPERGLYCEMIA; IMMUNOHISTOCHEMISTRY; INSULIN RESISTANCE; INSULIN SENSITIVITY; LEAN BODY WEIGHT; LIPID DIET; NON INSULIN DEPENDENT DIABETES MELLITUS; NONHUMAN; OBESITY; PANCREAS FUNCTION; PANCREAS ISLET; PANCREAS ISLET BETA CELL; QUANTITATIVE ANALYSIS; RAT; SINGLE DRUG DOSE;

EID: 77957254503     PISSN: 14628902     EISSN: 14631326     Source Type: Journal    
DOI: 10.1111/j.1463-1326.2010.01291.x     Document Type: Article

References (39)

1. Bays H. From victim to ally: the kidney as an emerging target for the treatment of diabetes mellitus. Curr Med Res Opin 2009, 25:671-681..
2. Kanai Y, Lee WS, You G, Brown D, Hediger MA. The human kidney low affinity Na+/glucose cotransporter SGLT2. Delineation of the major renal reabsorptive mechanism for D-glucose. J Clin Invest 1994, 93:397-404..
3. Hermansen K, Mortensen LS. Bodyweight changes associated with antihyperglycaemic agents in type 2 diabetes mellitus. Drug Saf 2007, 30:1127-1142..
4. Arakawa K, Ishihara T, Oku A. Improved diabetic syndrome in C57BL/KsJ-db/db mice by oral administration of the Na(+)-glucose cotransporter inhibitor T-1095. Br J Pharmacol 2001, 132:578-586..
5. Nunoi K, Yasuda K, Adachi T. Beneficial effect of T-1095, a selective inhibitor of renal Na+-glucose cotransporters, on metabolic index and insulin secretion in spontaneously diabetic GK rats. Clin Exp Pharmacol Physiol 2002, 29:386-390..
6. Ueta K, Ishihara T, Matsumoto Y. Long-term treatment with the Na+-glucose cotransporter inhibitor T-1095 causes sustained improvement in hyperglycemia and prevents diabetic neuropathy in goto-kakizaki rats. Life Sci 2005, 76:2655-2668..
7. Fujimori Y, Katsuno K, Nakashima I, Ishikawa-Takemura Y, Fujikura H, Isaji M. Remogliflozin etabonate, in a novel category of selective low-affinity sodium glucose cotransporter (SGLT2) inhibitors, exhibits antidiabetic efficacy in rodent models. J Pharmacol Exp Ther 2008, 327:268-276..
8. Fujimori Y, Katsuno K, Ojima K. Sergliflozin etabonate, a selective SGLT2 inhibitor, improves glycemic control in streptozotocin-induced diabetic rats and Zucker fatty rats. Eur J Pharmacol 2009, 609:148-154..
9. Han S, Hagan DL, Taylor JR. Dapagliflozin, a selective SGLT2 inhibitor, improves glucose homeostasis in normal and diabetic rats. Diabetes 2008, 57:1723-1729..
10. Idris I, Donnelly R. Sodium-glucose co-transporter-2 inhibitors: an emerging new class of oral antidiabetic drug. Diabetes Obes Metab 2009, 11:79-88..
11. Wilding JP, Norwood P, T'joen C, Bastien A, List JF, Fiedorek FT. A study of dapagliflozin in patients with type 2 diabetes receiving high doses of insulin plus insulin sensitizers: applicability of a novel insulin-independent treatment. Diabetes Care 2009, 32:1656-1662..
12. Effect of intensive blood-glucose control with metformin on complications in overweight patients with type 2 diabetes (UKPDS 34). Lancet 1998, 352:854-865.. UK Prospective Diabetes Study (UKPDS) Group.
13. Butler AE, Janson J, Bonner-Weir S, Ritzel R, Rizza RA, Butler PC. Beta-cell deficit and increased beta-cell apoptosis in humans with type 2 diabetes. Diabetes 2003, 52:102-110..
14. Kjorholt C, Akerfeldt MC, Biden TJ, Laybutt DR. Chronic hyperglycemia, independent of plasma lipid levels, is sufficient for the loss of beta-cell differentiation and secretory function in the db/db mouse model of diabetes. Diabetes 2005, 54:2755-2763..
15. Jonas JC, Sharma A, Hasenkamp W. Chronic hyperglycemia triggers loss of pancreatic beta cell differentiation in an animal model of diabetes. J Biol Chem 1999, 274:14112-14121..
16. Rossetti L, Shulman GI, Zawalich W, DeFronzo RA. Effect of chronic hyperglycemia on in vivo insulin secretion in partially pancreatectomized rats. J Clin Invest 1987, 80:1037-1044..
17. Janssen SW, Martens GJ, Sweep CG, Span PN, Verhofstad AA, Hermus AR. Phlorizin treatment prevents the decrease in plasma insulin levels but not the progressive histopathological changes in the pancreatic islets during aging of Zucker diabetic fatty rats. J Endocrinol Invest 2003, 26:508-515..
18. Oku A, Ueta K, Nawano M. Antidiabetic effect of T-1095, an inhibitor of Na(+)-glucose cotransporter, in neonatally streptozotocin-treated rats. Eur J Pharmacol 2000, 391:183-192..
19. Adachi T, Yasuda K, Okamoto Y. T-1095, a renal Na+-glucose transporter inhibitor, improves hyperglycemia in streptozotocin-induced diabetic rats. Metabolism 2000, 49:990-995..
20. Oku A, Ueta K, Arakawa K. Correction of hyperglycemia and insulin sensitivity by T-1095, an inhibitor of renal Na+-glucose cotransporters, in streptozotocin-induced diabetic rats. Jpn J Pharmacol 2000, 84:351-354..
21. Corsetti JP, Sparks JD, Peterson RG, Smith RL, Sparks CE. Effect of dietary fat on the development of non-insulin dependent diabetes mellitus in obese Zucker diabetic fatty male and female rats. Atherosclerosis 2000, 148:231-241..
22. Teague J, Gyte A, Peel JE. Reversibility of hyperglycaemia and islet abnormalities in the high fat-fed female ZDF rat model of type 2 diabetes. J Pharm Tox Meth 2010, [Epub ahead of print].
23. Zhou YP, Madjidi A, Wilson ME. Matrix metalloproteinases contribute to insulin insufficiency in Zucker diabetic fatty rats. Diabetes 2005, 54:2612-2619..
24. Goh TT, Mason TM, Gupta N. Lipid-induced β-cell dysfunction in vivo in models of progressive β-cell failure. Am J Physiol 2007, 292:E549-E560..
25. Komoroski B, Vachharajani N, Boulton D. Dapagliflozin, a novel SGLT2 inhibitor, induces dose-dependent glucosuria in healthy subjects. Clin Pharmacol Ther 2009, 85:520-526..
26. Clark JB, Palmer CJ, Shaw WN. The diabetic Zucker fatty rat. Proc Soc Exp Biol Med 1983, 173:68-75..
27. Etgen GJ, Oldham BA. Profiling of Zucker diabetic fatty rats in their progression to the overt diabetic state. Metabolism 2000, 49:684-688..
28. Peterson RG, Shaw WN, Neel M, Little LA, Eichberg J. Zucker diabetic fatty rat as a model for noninsulindependent diabetes mellitus. ILAR News 1990, 32:16-19..
29. Rossetti L, Smith D, Shulman GI, Papachristou D, DeFronzo RA. Correction of hyperglycemia with phlorizin normalizes tissue sensitivity to insulin in diabetic rats. J Clin Invest 1987, 79:1510-1515..
30. Kahn SE, Prigeon RL, McCulloch DK. Quantification of the relationship between insulin sensitivity and beta-cell function in human subjects. Evidence for a hyperbolic function. Diabetes 1993, 42:1663-1672..
31. Jones CN, Pei D, Staris P, Polonsky KS, Chen YD, Reaven GM. Alterations in the glucose-stimulated insulin secretory dose-response curve and in insulin clearance in nondiabetic insulin-resistant individuals. J Clin Endocrinol Metab 1997, 82:1834-1838..
32. Kotronen A, Vehkavaara S, Seppala-Lindroos A, Bergholm R, Yki-Jarvinen H. Effect of liver fat on insulin clearance. Am J Physiol Endocrinol Metab 2007, 293:E1709-E1715..
33. Kaiser N, Yuli M, Uckaya G. Dynamic changes in β-cell mass and pancreatic insulin during the evolution of nutrition-dependent diabetes in Psammomys obesus: impact of glycemic control. Diabetes 2005, 54:138-145..
34. Topp BG, Atkinson LL, Finegood DT. Dynamics of insulin sensitivity, cell function, and cell mass during the development of diabetes in fa/fa rats. Am J Physiol Endocrinol Metab 2007, 293:E1730-E1735..
35. Sone H, Kagawa Y. Pancreatic beta cell senescence contributes to the pathogenesis of type 2 diabetes in high-fat diet-induced diabetic mice. Diabetologia 2005, 48:58-67..
36. Kargar C, Ktorza A. Anatomical versus functional beta-cell mass in experimental diabetes. Diabetes Obes Metab 2008, 10(Suppl. 4):43-53..
37. Pick A, Clark J, Kubstrup C. Role of apoptosis in failure of beta-cell mass compensation for insulin resistance and beta-cell defects in the male Zucker diabetic fatty rat. Diabetes 1998, 47:358-364..
38. Poitout V, Robertson RP. Minireview: secondary beta-cell failure in type 2 diabetes-a convergence of glucotoxicity and lipotoxicity. Endocrinology 2002, 143:339-342..
39. Harmon JS, Gleason CE, Tanaka Y, Poitout V, Robertson RP. Antecedent hyperglycemia, not hyperlipidemia, is associated with increased islet triacylglycerol content and decreased insulin gene mRNA level in Zucker diabetic fatty rats. Diabetes 2001, 50:2481-2486..